# ERRATA

**Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress**
SHI-FANG YAN, TOMOYUKI FUJITA, JIESHENG LU, KENJI OKADA, YU SHAN ZOU, NIGEL MACKMAN, DAVID J. PINSKY & DAVID M. STERN

*Nature Med.* 6, 1355-1361 (2000)

In Fig. 1, panels h and i are incorrect. The correct panels are shown here.




We regret this error.

**Genetic models for CNS inflammation**
TREVOR OWENS, HARTMUT WEKERLE & JACK ANTEL

*Nature Med.* 7, 161-166 (2001)

Table 4 was incorrect. The corrected Table 4 is shown here.

**Table 4** MS versus EAE

| Treatment | MS | | EAE | Transgenics or knockouts |
|---|---|---|---|---|
| | RR | SP | | |
| IFN-β | Alleviated[62] | No or minimal benefit[62] | Inhibited/ alleviated[62] | NR |
| IFN-γ | Exacerbated[63] | Transient worsening only[a] | Inflammatory (intra-CNS)[23,24] Suppressive (intraventricular)[25] | Inflammatory[22,28] in transgenics |
| IFN-γ blockade | Alleviated[62,b] | NR | Exacerbated[39,40] | Knockouts[35,36] generate a novel disease |
| TNF-α | NR | NR | Inhibited[15] | Inflammatory[10,58] in transgenics |
| TNF-α blockade | Exacerbated[67] sTNFRI-IgG | Exacerbated[68] Anti-TNF-α | Inhibited[6] | Gene knockouts show delayed or inhibited disease[13,14] |
| TGF-β | NR | No effect on MS Nephrotoxic[68] | Inhibited/alleviated[55,56] | Inflammatory[54] in transgenics |

[a]Treatment with IFNγ inducer Poly-ICLC (ref. 64) [b]IFN-β suppresses IFN-γ production[62], and this has been invoked as one possible cause of therapeutic benefit. IFN-β may also act via inhibition of leukocyte extravasation. RR, relapsing/remitting. SP, secondary progressive.

We regret this error.